Nursing notes: High-Risk Pregnancy, Diabetes, Hypertension, and Substance Use

High-Risk Pregnancy: Definition and Scope

  • High-risk pregnancy definition: a pregnancy in which the life or health of the mother, fetus, or both is jeopardized by a disorder or a condition that is coincidental with or unique to pregnancy.

  • Conditions that can cause a pregnancy to be at risk include:

    • Hypertension (chronic or gestational)

    • Diabetes mellitus (type 1, type 2, or gestational)

    • Cardiac disease

    • Renal disorders

    • Autoimmune diseases

    • Thyroid disorders

    • Obesity or underweight

    • Mental health disorders (depression, anxiety)

    • Substance use

  • Pregnancy-related complications to monitor for:

    • Hyperemesis gravidarum

    • Hemorrhagic events: placenta previa, placental abruption

    • Infections: TORCH infections, UTIs, HIV

    • Multiple gestation

    • Preterm labor and premature rupture of membranes (PROM)

    • Fetal growth restriction (FGR)

    • Isoimmunization

    • Preeclampsia and eclampsia

    • Amniotic fluid abnormalities: oligohydramnios, polyhydramnios

  • Demographic risk factors:

    • Maternal age <17 or >35

    • Lack of prenatal care

    • Low socioeconomic status

    • Intimate partner violence

    • Teenage pregnancy

  • Nursing role in high-risk pregnancy:

    • Assessment: frequent, comprehensive assessments; monitor vital signs and weight; fetal heart rate monitoring (intermittent or continuous); fundal height; fetal movement; lab monitoring (CBC, urine protein, glucose); monitor for signs of complications (headache, blurred vision, bleeding, decreased fetal movement).

    • Planning and prioritization: identify actual and potential complications; collaborate with interdisciplinary team (OB, MFM, endocrinology, dietitian, social worker); educate and involve patient and family in plan of care.

Diabetes in Pregnancy

  • Classifications:

    • Pregestational diabetes: type 1 or type 2 existing before pregnancy

    • Gestational diabetes mellitus (GDM): glucose intolerance first recognized during pregnancy

  • Screening:

    • All with pregestational diabetes: screen at first prenatal visit

    • GDM screening routinely between 24 and 28 weeks gestation

    • Early screening before 24 weeks if high risk (to detect undiagnosed type 2 diabetes)

  • Why screen:

    • Detect undiagnosed type 2 diabetes early

    • Identify gestational diabetes (usually develops in second half of pregnancy due to increasing insulin resistance)

    • Initiate early management to prevent maternal and fetal complications

  • Early screening risk factors for early testing:

    • BMI ≥ 25

    • History of GDM or prior macrosomic infant (≥ 4000 g)

    • First-degree relative with diabetes

    • Hypertension, PCOS, history of unexplained stillbirths

    • Known impaired glucose tolerance or fasting glucose

    • High-risk race/ethnicity (e.g., African American, Latino, Native American, South/East Asian, or Pacific Islander)

  • Pathophysiology of diabetes in pregnancy:

    • Not a single disease but a metabolic state influenced by placental hormones, maternal insulin sensitivity, and β-cell reserve

    • Two main categories: pregestational diabetes and gestational diabetes

  • Normal metabolic changes in pregnancy:

    • Two phases: anabolic (early pregnancy) and catabolic (late pregnancy)

    • Hormones: increased estrogen and progesterone -> increased insulin sensitivity and β-cell hyperplasia -> increased insulin secretion

    • Metabolic effects: increased glycogen storage in liver/muscle; increased lipogenesis; decreased fasting glucose due to uptake by maternal tissues and fetus

  • Clinical correlation:

    • Women with preexisting type 1 diabetes may require lower insulin doses in the anabolic phase (risk of hypoglycemia)

  • Diabetes in pregnancy: catabolic phase (late pregnancy, >20 weeks):

    • Hormones rising: human placental lactogen (HPL), progesterone, estrogen, cortisol, placental growth hormone

    • Anti-insulin effects -> insulin resistance increases

    • Metabolic effects: ↑ lipolysis (↑ FFAs); ↑ hepatic gluconeogenesis (more glucose to fetus); ↓ maternal glucose uptake by muscle/fat

    • Insulin requirements rise progressively (often 2–4x baseline) in type 1

    • Hormonal contributions:

    • HPL: placental insulin antagonist -> ↑ lipolysis; ↓ maternal glucose uptake

    • Progesterone: ↑ insulin resistance; modulates β-cell function

    • Estrogen: promotes lipogenesis and insulin resistance

    • Cortisol: ↑ hepatic gluconeogenesis; ↓ glucose uptake

    • Placental growth hormone: promotes insulin resistance

  • Pathophysiology summary: progressive, hormone-driven insulin resistance; hepatic glucose output ↑; peripheral glucose utilization ↓; β-cell compensation may fail

  • Maternal and fetal consequences of diabetes in pregnancy:

    • Maternal: hyperglycemia -> osmotic diuresis, dehydration, electrolyte loss; lipolysis -> ketosis; risk of DKA; vascular complications (retinopathy, nephropathy, CV disease risk)

    • Obstetric complications: preeclampsia, polyhydramnios, preterm labor

    • Fetal/neonatal: maternal hyperglycemia -> fetal hyperglycemia -> fetal hyperinsulinemia -> macrosomia (> 4000 g); shoulder dystocia; organomegaly (liver, heart); neonatal hypoglycemia; RDS due to impaired surfactant; polycythemia; hyperbilirubinemia; chronic intrauterine hypoxia -> polycythemia; risk of stillbirth with poor glycemic control late in pregnancy

  • Timeline of insulin needs in diabetic pregnancy:

    • 1st trimester: decreased insulin need (↑ insulin sensitivity; high fetal glucose uptake)

    • 2nd trimester: gradual increase in insulin need (rising placental hormones)

    • Late 3rd trimester: sharp increase (2–4× baseline) due to peak insulin resistance

    • Immediate postpartum: drastic fall in insulin needs (loss of placental hormones; rapid normalization)

  • Nursing implications for diabetes in pregnancy:

    • Screening and glycemic targets; educate on glucose monitoring, diet, exercise, medication adherence

    • Fetal monitoring: growth scans and nonstress tests (NSTs) or biophysical profiles (BPP)

    • Labor management: maintain maternal glucose between 70–110 mg/dL; IV insulin may be needed; continuous fetal monitoring

    • Postpartum follow-up: 6–12 weeks OGTT to assess persistent diabetes; lifelong monitoring for gestational diabetes patient (risk of type 2 later in life)

  • Glycemic targets in pregnancy:

    • Fasting: <95 mg/dL< 95\ \text{mg/dL}

    • 1 hour postprandial: <140 mg/dL< 140\ \text{mg/dL}

    • 2 hour postprandial: <120 mg/dL< 120\ \text{mg/dL}

    • Bedtime/pre-meal: 60-99 mg/dL60\text{-}99\ \text{mg/dL}

  • Assessment framework for diabetes in pregnancy:

    • Subjective data: prepregnancy diagnosis, prior pregnancies, family history, upstitcher history, prior GDM/macrosomia, polyhydramnios, current pregnancy symptoms (polyuria, polydipsia, fatigue, vision changes, fetal movement changes)

    • Objective data: vital signs, BP, weight; labs (fasting glucose, 1h/2h postprandial, HbA1c); urinalysis for glucose/ketones/protein; renal function (BUN, creatinine); 24h urine protein if indicated; electrolytes if concerned about DKA

    • Physical assessment: appearance (fatigued/dehydrated), skin (poor healing), abdominal findings (fundal height, fetal growth), fetal movements, fetal heart tones, edema, reflexes (hyperreflexia may signal preeclampsia), vascular signs; fetal assessment (ultrasound in 2nd/3rd trimester for growth, amniotic fluid volume, anatomy; BPP; NST; kick counts; Doppler for placental insufficiency)

  • Monitoring schedule and red flags:

    • Prenatal visits: weight, BP, urine dip for glucose/protein/ketones; insulin adjustments if needed; review glucose logs

    • 28–32 weeks: kick counts and growth ultrasound

    • 32–36 weeks: NST or BPP

    • 36 weeks+: weekly or biweekly NSTs; delivery planning; fetal surveillance for macrosomia, amniotic fluid volume, IUGR; Doppler studies if indicated

    • Postpartum: OGTT at 6–12 weeks; continue screening every 1–3 years for type 2 risk

    • Red flags: persistent hyperglycemia or ketonuria; reduced fetal movement; preeclampsia signs (headache, visual changes, RUQ pain, BP elevation, proteinuria); signs of DKA; preterm labor symptoms

  • Goals of treatment:

    • Maintain maternal euglycemia

    • Prevent maternal complications (preeclampsia, DKA, infection)

    • Prevent fetal/neonatal complications (macrosomia, hypoglycemia, stillbirth)

    • Support fetal growth and safe labor/delivery

  • Treatment components:

    • Medical Nutrition Therapy (MNT): individualized meal plan by a registered dietitian; goal to stabilize glucose and appropriate weight gain

    • General recommendations: three small meals + 2–3 snacks daily; complex carbohydrates 40–50%; protein 20–25%; fats 30–40%

    • Avoid simple sugars and refined carbs; emphasize low glycemic index foods; include bedtime snack to prevent ketosis

    • Physical activity: moderate activity (e.g., walking, swimming, prenatal yoga) 30 minutes/day, 5–7 days/week; improves insulin sensitivity and lowers postprandial glucose

    • Glucose monitoring targets (as above)

    • Pharmacotherapy:

    • First-line: insulin (preferred; does not cross placenta)

    • Rapid-acting insulins: Lispro or Aspart for postprandial spikes

    • Intermediate-acting: NPH for basal control

    • Long-acting: Detemir (used in pregestational diabetes)

    • Dosing: adjusted frequently due to changing insulin resistance

    • Oral hypoglycemics: second-line/adjunct (not FDA-approved for pregnancy but used off-label when insulin is refused or not feasible)

      • Metformin: crosses placenta; minimal adverse fetal outcomes

      • Glyburide (glibenclamide): older option; higher risk of neonatal hypoglycemia

    • Fetal surveillance during treatment: kick counts and growth ultrasounds every 4–6 weeks; NSTs and BPP in late pregnancy, especially if on medications; monitor amniotic fluid index

    • Intrapartum management: monitor glucose every 1–2 hours during labor; maintain maternal glucose between 70–110 mg/dL; IV insulin or dextrose drip as needed; vaginal delivery preferred unless obstetric indication for cesarean

    • Postpartum management: most women return to normal glucose tolerance within 24–72 hours; discontinue insulin postpartum unless hyperglycemia persists; continue glucose screening and postpartum follow-up; lifelong lifestyle counseling

  • Gestational Diabetes Mellitus (GDM): pathophysiology and differences from pregestational diabetes

    • GDM is glucose intolerance first recognized during pregnancy, developing in mid-to-late pregnancy when insulin resistance is highest

    • Usually resolves after delivery but increases lifetime risk of type 2 diabetes (35–60% risk within 10–20 years)

    • Pathophysiology recap: placental hormones (HPL, progesterone, estrogen, cortisol, placental growth hormone) cause progressive insulin resistance; β-cell compensation may be insufficient -> hyperglycemia -> placental glucose transfer -> fetal hyperinsulinemia -> macrosomia

    • Fetal/neonatal consequences include macrosomia, shoulder dystocia, neonatal hypoglycemia, RDS, polycythemia, hyperbilirubinemia, hypocalcemia, hypomagnesemia; long-term risks include obesity and impaired glucose tolerance

    • Screening/timing: same targets as above; risk-based early screening as noted

    • Diagnostic and management focus:

    • MNT and physical activity as first-line therapy

    • Glucose monitoring targets identical to those for pregnancy with diabetes

    • Pharmacologic therapy if needed (insulin preferred; oral agents used off-label in some cases)

    • Fetal surveillance (kick counts, growth ultrasounds; NST/BPP; Doppler studies as indicated)

    • Intrapartum management similar to pregestational diabetes when insulin-dependent or poorly controlled

    • Delivery planning: timing guided by maternal glycemic control and fetal status; often delivery near term if well-controlled

    • Postpartum: GDM typically resolves; assess with 75 g OGTT at 6–12 weeks; ongoing risk for type 2 diabetes with long-term follow-up and lifestyle counseling

  • Chronic Hypertension in Pregnancy

    • Definition: hypertension present before pregnancy or diagnosed before 20 weeks or persisting beyond 12 weeks postpartum

    • Diagnostic criteria: systolic ≥

    • SBP ≥ 140 mmHg or DBP ≥ 90 mmHg on at least two occasions ≥ 4 hours apart

    • Pathophysiology: increased peripheral vascular resistance and/or increased cardiac output due to chronic vascular remodeling

    • Pregnancy impact: normal pregnancy causes vasodilation and BP drop in 1st trimester; chronic HTN blunts this, risking placental insufficiency

    • Cellular/vascular changes: endothelial dysfunction, arterial stiffness, chronic inflammation

    • Risk of superimposed preeclampsia

    • Risk factors: maternal age > 35, pre-pregnancy BMI > 30, African American, family history of hypertension, prior preeclampsia, diabetes, CKD, connective tissue disorders, thyroid disorders, high-sodium diet, sedentary lifestyle, smoking

    • Maternal complications: superimposed preeclampsia, placental abruption, preterm labor, stroke, chronic kidney disease progression, cardiomyopathy

    • Fetal/neonatal complications: FGR, oligohydramnios, preterm birth, stillbirth

    • Management:

    • Preconception: optimize BP, switch to pregnancy-safe antihypertensives (labetalol, nifedipine, methyldopa); avoid ACE inhibitors, ARBs, direct renin inhibitors; lifestyle modifications

    • Antenatal: treat severe BP (≥ 160/110) promptly; target BP roughly 120–160 systolic and 80–105 diastolic; low-dose aspirin 81 mg daily from 12–16 weeks to reduce preeclampsia risk

    • Fetal surveillance: growth ultrasounds every 4 weeks from 28–32 weeks; NST/BPP 32–34 weeks; hospitalize for severe hypertension or fetal compromise

    • Intrapartum: continue antihypertensives; avoid maternal hypotension; vaginal delivery preferred unless obstetric indication for cesarean

    • Postpartum: BP normalization by ~12 weeks postpartum; monitor for persistent hypertension and long-term cardiovascular risk; adjust antihypertensives for breastfeeding safety (labetalol, nifedipine, methyldopa are compatible with lactation)

    • Key nursing points: accurate BP measurement; assess for preeclampsia signs; promote home BP monitoring; advise on low-sodium diet and hydration; encourage moderate activity unless contraindicated

  • Gestational Hypertension

    • Definition: new-onset hypertension after 20 weeks without proteinuria or signs of end-organ dysfunction

    • Diagnostic criteria: SBP ≥ 140 mmHg or DBP ≥ 90 mmHg on two occasions at least 4 hours apart after 20 weeks gestation

    • Typically resolves within 12 weeks postpartum

    • If proteinuria or systemic involvement develops, progression to preeclampsia

    • Pathophysiology: abnormal placental vascular remodeling and maternal vascular dysfunction; placenta may release anti-angiogenic factors -> systemic vasoconstriction

    • Diagnostic criteria for proteinuria if present: ≥ 300 mg/24 h or protein/creatinine ratio ≥ 0.3 or dipstick ≥ 1+

    • If thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema, or neurologic symptoms develop, diagnosis may shift toward preeclampsia

    • Risk factors: first pregnancy, maternal age < 20 or > 40, multifetal gestation, obesity (BMI > 30), family history of preeclampsia, prior GH, metabolic syndrome/insulin resistance

    • Maternal complications: progression to preeclampsia or eclampsia, placental abruption, HELLP, stroke, CV events

    • Fetal complications: FGR, oligohydramnios, preterm birth, fetal demise

    • Management:

    • Outpatient: home BP monitoring; weekly to biweekly prenatal visits; serial urine tests; fetal surveillance (NST, BPP, growth ultrasounds every 3–4 weeks)

    • Inpatient: for severe hypertension or fetal compromise

    • Antihypertensive therapy as indicated; delivery timing individualized by maternal/fetal status

  • Preeclampsia and Eclampsia

    • Preeclampsia definition: new-onset hypertension after 20 weeks with proteinuria or signs of end-organ dysfunction in the absence of another explanation

    • Diagnostic criteria: BP ≥ 140/90 on two occasions ≥ 4 hours apart after 20 weeks; proteinuria ≥ 300 mg/24h or protein/creatinine ratio ≥ 0.3 or dipstick ≥ 1+; without proteinuria, presence of thrombocytopenia, renal impairment, hepatic dysfunction, pulmonary edema, or new CNS/visual disturbances

    • Pathophysiology: abnormal placentation -> shallow trophoblastic invasion -> narrow/high-resistance spiral arteries -> placental ischemia -> angiogenic/inflammatory mediator release -> systemic endothelial dysfunction -> edema, vasoconstriction, multi-organ involvement

    • Maternal complications: eclampsia, HELLP, stroke, DIC, placental abruption, liver hematoma/rupture, renal failure

    • Fetal complications: FGR, oligohydramnios, preterm birth, intrauterine fetal demise, placental insufficiency

    • Management by features:

    • Preeclampsia without severe features: aim to prolong pregnancy to allow fetal maturation with close monitoring; frequent BP and urine protein checks; fetal surveillance (NST, ultrasound); plan delivery at ≥ 37 weeks if stable

    • Preeclampsia with severe features: hospitalization; antihypertensives (labetalol, hydralazine, or nifedipine); magnesium sulfate for seizure prophylaxis; administer corticosteroids if < 34 weeks for fetal lung maturity; delivery at 34 weeks or sooner if unstable

    • Intrapartum: continuous fetal monitoring; maintain BP < 160/110; continue magnesium sulfate during labor and for 24 hours postpartum

    • Postpartum: BP may remain elevated for days to weeks; monitor for late eclampsia up to 6 weeks postpartum; counseling on long-term cardiovascular risk

    • HELLP syndrome (a severe form/complication of preeclampsia or eclampsia)

    • Definition: Hemolysis, Elevated Liver enzymes, Low Platelets

    • Occurs in ~10–20% of women with severe preeclampsia

    • Pathophysiology: endothelial dysfunction with microvascular injury -> hepatic ischemia/necrosis -> elevated AST/ALT; coagulation cascade activation -> thrombocytopenia; schistocytes and hemolysis -> low haptoglobin, elevated LDH, indirect bilirubin

    • Clinical features: malaise, nausea/vomiting, RUQ or epigastric pain; hypertension may be present or not

    • Diagnosis labs: elevated LDH; fragmented RBCs on smear; low haptoglobin; elevated AST/ALT; platelets < 100,000/mm³; other labs: uric acid, bilirubin, prolonged coagulation times

    • Maternal complications: DIC, hepatic hematoma/rupture, acute renal failure, pulmonary edema, placental abruption, stroke, death

    • Fetal complications: prematurity, IUGR, stillbirth

    • Management: immediate hospitalization and stabilization; delivery is definitive treatment; BP control; MgSO₄; transfusion if platelets very low or bleeding risk; monitor liver/renal function and coagulation; fetal status with continuous monitoring

    • Nursing considerations: monitor for worsening liver injury/bleeding; assess neurologic status; prepare for potential emergency cesarean; patient and family education; supportive care

  • Iron-Deficiency Anemia in Pregnancy

    • Cause/risk: insufficient iron intake; pregnancy increases iron needs due to expanded maternal blood volume and fetal demands; other risks include blood loss, vegetarian diet, GI malabsorption, heavy menses, GI bleeding, bariatric surgery, Crohn’s disease, etc.

    • Role of iron: essential for hemoglobin synthesis; deficiency leads to microcytic, hypochromic RBCs and reduced oxygen delivery

    • Clinical manifestations: fatigue, pallor, dyspnea on exertion, dizziness, pica, glossitis, angular cheilitis, brittle nails, tachycardia

    • Lab findings: CBC with low Hb/Hct and microcytic, hypochromic indices; iron studies show low ferritin, low serum iron, high TIBC, low transferrin saturation

    • Diagnosis: CBC and iron studies; stool occult blood or endoscopy if indicated

    • Treatment:

    • Address underlying cause

    • Iron supplementation (oral ferrous sulfate) with vitamin C; avoid calcium with iron supplements

    • Dietary counseling and iron-rich foods

    • Nursing considerations:

    • Ensure compliance and manage GI side effects (constipation, dark stools, GI upset)

    • Monitor Hb and ferritin levels during treatment; assess ongoing blood loss in pregnancy

    • For pregnant women: ensure prenatal vitamins contain adequate iron

    • Complications if untreated: heart failure; impaired fetal cognitive/physical development; preterm birth; low birth weight; increased maternal/fetal risks

  • Vulnerable Populations in Pregnancy

    • Pregnant adolescents

    • Nursing assessment: build rapport; nonjudgmental approach; ensure privacy; age-appropriate language

    • Health history focus: gestational age, prenatal care history, STIs, contraception use, medical/surgical history, immunizations, menstrual history, psychosocial factors, social support and living situation

    • Psychosocial: screen for depression, anxiety, abuse; assess coping, readiness for behavioral changes; assess knowledge about prenatal and newborn care

    • Physical examination: vital signs; pallor; thyroid; breast development; abdominal exam; fundal height; fetal heart tones; fetal position; edema; varicosities; reflexes; signs of vascular compromise

    • Labs: urine dipstick (protein, glucose, ketones); CBC with Hb/Hct; blood type and Rh; STI screening; gestational diabetes screening; iron, folate, vitamin D as indicated

    • Interventions: tailored education on prenatal care, nutrition, and lifestyle; facilitate access to support services; counseling, WIC; monitor for depression/abuse; encourage continued schooling if possible; promote regular prenatal visits

    • Pregnant women aged >35 (Advanced Maternal Age, AMA)

    • AMA pregnancy: enhanced surveillance and individualized care

    • Risk factors: chromosomal abnormalities, pregnancy complications, adverse outcomes

    • Comprehensive health assessment: obstetric/gynecologic history; prior pregnancy outcomes; preexisting conditions (HTN, diabetes, thyroid disease); family history of genetic disorders; lifestyle factors (smoking, alcohol, drugs); medications/supplements

    • Physical assessment: baseline vitals, weight/BMI, cardiac/respiratory/abdominal exam; fundal height and fetal heart tones

    • Laboratory/diagnostic tests: early prenatal genetic screening; glucose tolerance test for GDM; CBC, thyroid function, infectious disease screening; ultrasound for fetal anatomy and growth; regular fetal well-being assessments

    • Education/support: genetic testing options; informed decision-making; monitor for GDM and HTN/preeclampsia; watch for preterm labor, placenta previa/abruption; risk of miscarriage or stillbirth; possibility of cesarean delivery; discuss lifestyle modifications (folic acid, iron, calcium; physical activity; smoking cessation; alcohol avoidance)

    • Postpartum planning: breastfeeding support; contraception counseling

    • Psychosocial: assess stress, anxiety, depression; ensure support networks and involvement in childbirth education for AMA

    • Substance use during pregnancy

    • Substances and effects:

      • Alcohol: maternal nutritional deficiencies and hypertension; fetal alcohol spectrum disorders (FASD); growth restriction and neurodevelopmental delays

      • Tobacco: placental abruption, preterm labor; fetal effects include low birth weight, IUGR, SIDS risk

      • Cocaine: vasoconstriction and placental abruption; preterm birth, growth restriction, CNS abnormalities

      • Opioids: infection risk, overdose; neonatal abstinence syndrome (NAS); preterm birth

      • Marijuana: possible impaired fetal growth; potential cognitive/behavioral issues

      • Methamphetamine: maternal hypertension/preeclampsia risk; fetal growth restriction, preterm birth, neurodevelopmental delays

    • Nursing assessment and management:

      • Obtain nonjudgmental, thorough substance use history; screen with validated tools

      • Assess prenatal care adequacy and nutritional status; monitor withdrawal or intoxication signs

      • Evaluate mental health status and coexisting psychiatric disorders; assess social support and living environment

      • Plan for safe detoxification with addiction specialists if indicated; coordinate with social work and obstetric team

      • Develop plan for pain management in labor (avoid opioids if possible for opioid users); plan for neonatal withdrawal after birth

      • Postpartum: monitor for NAS in newborns; promote continuity of prenatal care; referrals to addiction treatment and support groups; contraception counseling; screen for postpartum depression

      • Legal/ethical: understand local laws; advocate while maintaining confidentiality; prepare for mandatory reporting if applicable

  • Fetal Alcohol Spectrum Disorders (FASD)

    • Fetal Alcohol Syndrome (FAS) is the most severe form of FASD

    • Causes physical, cognitive, and behavioral abnormalities due to prenatal alcohol exposure

    • Alcohol crosses placenta and disrupts cell proliferation, migration, and differentiation during organogenesis

    • Features and risk factors:

    • Facial features: smooth philtrum, thin vermilion border, small palpebral fissures

    • Midface hypoplasia; small jaw; growth deficiency; CNS abnormalities

    • CNS: microcephaly, abnormal brain morphology, cognitive and behavioral deficits; learning difficulties, attention deficits, hyperactivity

    • Risk factors: amount, frequency, and timing of alcohol intake (especially 1st trimester); genetic susceptibility; poor maternal nutrition; lack of prenatal care

    • Complications: lifelong cognitive/behavioral problems, school difficulties, social adaptation issues, increased risk of mental health disorders, potential seizures

    • Diagnosis: clinical criteria combining confirmed prenatal alcohol exposure, facial features, growth deficits, and CNS dysfunction

    • Management: multidisciplinary approach (special education, therapy, mental health support, family counseling, social support)

    • Prevention: avoid alcohol entirely during pregnancy; public health education; screening and counseling for women of childbearing age; early diagnosis and intervention when needed

  • Key takeaways

    • Gestational diabetes develops after organogenesis and usually does not cause congenital malformations; placental hormones drive insulin resistance

    • Major fetal complications include macrosomia and neonatal hypoglycemia; lifelong type 2 diabetes risk for mother and child exists after GDM

    • Blood glucose targets in pregnancy are stricter than in nonpregnant adults; delivery planning depends on maternal/fetal status

    • Chronic hypertension and gestational hypertension carry risks for preeclampsia, placental pathologies, and fetal complications; aspirin prophylaxis reduces preeclampsia risk

    • Preeclampsia requires delivery as the only definitive cure when severe

    • HELLP is a severe complication of preeclampsia/eclampsia requiring urgent management

    • Iron-deficiency anemia in pregnancy demands iron supplementation and dietary changes to prevent maternal and fetal adverse outcomes

    • Adolescent and AMA pregnancies require tailored assessment, education, and enhanced surveillance

    • Substance use during pregnancy poses significant maternal and fetal risks; a nonjudgmental, multidisciplinary approach improves engagement and outcomes

    • FASD represents lifelong implications; prevention through abstaining from alcohol during pregnancy is essential